Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock Has Consensus Target Price of $31.29 According to Analysts

Key Points

• Analyst consensus is “Moderate Buy”: 16 firms cover Dyne Therapeutics, with 12 buy or strong-buy ratings, two holds, and two sells. The average one-year price target is $31.29.
• Recent analyst targets vary: Piper Sandler set a $47 target, while RBC cut its target to $30 and Robert W. Baird lowered its target to $26; both retained outperform ratings.
• Insiders sold about 2.6 million shares worth $65.4 million over the past three months. Director Jason P. Rhodes accounted for a large sale, reducing his stake by 83.43%; the CEO’s smaller sale was to cover tax withholding on vested equity awards.

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have received an average recommendation of "Moderate Buy" from the sixteen ratings firms that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, two have issued a hold recommendation, eleven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $31.29.

A number of brokerages have recently commented on DYN. Royal Bank Of Canada dropped their price objective on shares of Dyne Therapeutics from $35.00 to $30.00 and set an "outperform" rating on the stock in a research note on Wednesday, September 9th. Wall Street Zen cut shares of Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 1st. Piper Sandler reiterated an "overweight" rating and issued a $47.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, September 29th. Robert W. Baird lowered their price target on shares of Dyne Therapeutics from $30.00 to $26.00 and set an "outperform" rating on the stock in a report on Wednesday, September 9th. Finally, Raymond James Financial restated a "strong-buy" rating and set a $37.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, September 8th.

Insider Activity

In other news, CEO John Cox sold 5,658 shares of the firm's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total transaction of $106,823.04. Following the sale, the chief executive officer directly owned 357,507 shares in the company, valued at $6,749,732.16. This trade represents a 1.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jason P. Rhodes sold 2,160,516 shares of the business's stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $25.00, for a total value of $54,012,900.00. Following the completion of the sale, the director owned 428,946 shares of the company's stock, valued at $10,723,650. This trade represents a 83.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,598,706 shares of company stock worth $65,432,671 over the last three months. Corporate insiders own 9.46% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in DYN. Pictet Asset Management Holding SA lifted its stake in Dyne Therapeutics by 7.4% in the 3rd quarter. Pictet Asset Management Holding SA now owns 20,805 shares of the company's stock valued at $335,000 after buying an additional 1,433 shares in the last quarter. Alps Advisors Inc. boosted its holdings in Dyne Therapeutics by 48.1% in the 3rd quarter. Alps Advisors Inc. now owns 247,403 shares of the company's stock worth $3,986,000 after buying an additional 80,321 shares during the last quarter. CenterBook Partners LP increased its stake in Dyne Therapeutics by 167.7% during the 3rd quarter. CenterBook Partners LP now owns 57,650 shares of the company's stock worth $929,000 after buying an additional 36,112 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Dyne Therapeutics during the 3rd quarter worth approximately $154,000. Finally, Profund Advisors LLC increased its stake in Dyne Therapeutics by 13.9% during the 3rd quarter. Profund Advisors LLC now owns 67,005 shares of the company's stock worth $1,079,000 after buying an additional 8,195 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Stock Up 2.7%

Shares of DYN stock opened at $18.54 on Thursday. Dyne Therapeutics has a twelve month low of $14.00 and a twelve month high of $27.31. The stock has a market cap of $3.46 billion, a P/E ratio of -5.57 and a beta of 1.22. The stock has a 50 day moving average of $18.04 and a 200 day moving average of $19.32. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for serious muscle diseases. The company's research is centered on conditions in which the delivery of therapeutic molecules to skeletal muscle and other tissues is a significant challenge.

Dyne uses its proprietary FORCE platform to design targeted therapies intended to improve the delivery of oligonucleotides into muscle cells. The platform incorporates antibodies that bind to the transferrin receptor, which can help transport genetic medicines across cell membranes and into muscle tissue.

Dyne's pipeline includes DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.